New NHS Alliance Responds To Accelerated Access Review (AAR) Funding Announcement

July 14, 2017

The New NHS Alliance would like to support and welcome the investment to speed up access to innovative medicines and technology.

The NNHSA  recognise the need to do things differently. We desperately need to support the introduction and spread of innovative new medicines and technologies throughout the NHS. We support the Government’s ambition that NHS patients should get world-leading, life-changing treatments as fast as possible. We now have an NHS innovation accelerator and an innovation network: it is fundamental to support their work through reducing the funding barriers within the NHS.  We also see the importance to companies that invest their own money in the development of innovative new medicines and technologies and agree that we should support these companies to make the UK a global centre for life sciences and a country renowned for innovative solutions.

Mark Robinson, NNHSA lead on pharmacy, commented:

“Innovation should be seen as a responsibility and not an option. We welcome this support to ensure that we can develop innovative medicines and technologies that support the way that we deliver healthcare and create health. We are entering an exciting time where innovation will change the face of people’s lives and the way that the NHS performs.”